RxDoctor Payments Data

Erin McBride

Family · Charleston, SCNPI 1841754595

Payments from drug & device makers

$2,130in general payments, 2019–2025

Across 102 payments — averaging $20.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$577
  • Viiv Healthcare Company$388
  • Novo Nordisk$148
  • Takeda Pharmaceuticals U.S.A., Inc.$142
  • AbbVie$89
  • Biohaven Pharmaceuticals, Inc.$89
  • plus $698 from 19 others

What the payments were for

  • Food & beverage$2,130100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,130 in reported general payments places this provider in the 80th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$9,092
Medicare patients
58
Services billed
170

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala78$303,106
OdefseyEmtricitab/Rilpiviri/Tenof Ala16$55,586
JulucaDolutegravir/Rilpivirine12$40,544
JardianceEmpagliflozin29$36,300
DovatoDolutegravir Sodium/Lamivudine11$31,432
JanuviaSitagliptin Phosphate18$26,612
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$25,783
FarxigaDapagliflozin Propanediol12$20,258
TrulicityDulaglutide11$18,114
MyrbetriqMirabegron17$13,576
SymbicortBudesonide/Formoterol Fumarate14$4,809
Albuterol Sulfate HfaAlbuterol Sulfate56$1,771
Fluticasone Propionate80$1,357
Atorvastatin Calcium178$1,187
Rosuvastatin Calcium105$900

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$577$303,10678 claims
Viiv Healthcare CompanyJuluca, Dovato$388$71,97523 claims
Boehringer IngelheimJardiance$22$36,30029 claims
MerckJanuvia$22$26,61218 claims
GSKTrelegy Ellipta$31$25,78320 claims
AstraZenecaFarxiga, Symbicort$66$25,06726 claims
Lilly USA, LLCTrulicity$79$18,11411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,248 family providers in South Carolina.

Other family in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →